Marker Therapeutics Inc (MRKR)

[Bio7mm]

Impressive list of competitive advantages from a PR when Tapimmune was GeneMax Corp on Sept. 9, 2003. Just shows how long it takes these biotechs to get the stars aligned but I think TPIV is getting ready to roll:

Based on cancer incidence data collected for the year 2000 from a Lyon, IARCPress document of 2001, the Company's TAP cancer technology, if successful, may form a relevant immunotherapy for 60%-70% of all new incidences of cancer in the US, Japan, and the four major European markets. The competitive advantages include: efficacy against secondary cancerous growths elsewhere in the body, no restrictions on the patient's HLA type, no restrictions regarding the genetics of the tumors, and non-toxicity to normal cells. The technology is complementary and synergistic with all other immunotherapies dependent on cytotoxic T cell killing and also has the potential to enable a variety of tumor antigen vaccines.